Details for Patent: 9,855,258

Which drugs does patent 9,855,258 protect, and when does it expire?

Patent 9,855,258 protects RELEXXII and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 9,855,258

Title:	Dose-dumping resistant controlled release dosage form
Abstract:	The present invention provides a simple and improved dosage form that is capable of providing a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
Inventor(s):	Hernan D. Benedetti, Cristian R. FRANCO, Guido S. BIGATTI, Joaquina Faour, Ana C. PASTINI
Assignee:	Acella Pharmaceuticals LLC
Application Number:	US15/624,209
Patent Claim Types: see list of patent claims	Use; Device; Dosage form;

error: insufficient information

Drugs Protected by US Patent 9,855,258

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-001	Jun 23, 2022		RX	Yes	No	9,855,258		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-002	Jun 23, 2022		RX	Yes	No	9,855,258		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-003	Jun 23, 2022		RX	Yes	No	9,855,258		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-004	Jun 23, 2022		RX	Yes	No	9,855,258		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-005	Jun 23, 2022		RX	Yes	No	9,855,258		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Osmotica Pharm Us	RELEXXII	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216117-006	Jun 23, 2022		RX	Yes	No	9,855,258		Y			TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

International Family Members for US Patent 9,855,258

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	109157
Canada	2992767
Chile	2017001919
Uruguay	37344